Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine in Low- or Intermediate-risk MDS
NCT05469737Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2022
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of CC-486 in myelodysplastic syndrome (MDS), sponsored by Bristol Myers Squibb. Started Dec 2022; status: active, not recruiting.
02
Drugs
CC-486
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05469737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469737.